BridgeMD
New treatment option for Advanced or Metastatic Breast Cancer
Official title A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
ClinicalTrials.gov ID: NCT05187832
What this study is testing
What is AND019 PO QD?
AND019 PO QD is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for advanced or metastatic breast cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Postmenopausal women defined as NCCN guideline at the time of informed consent.
- Histological or cytological confirmation of advanced or metastatic ER+/HER2- breast cancer women who failed standard therapy or for which no standard...
- Prior therapy:
- No more than 1 line of chemotherapy for advanced breast cancer
- Recurrence or progression on at least one line of endocrine therapy in the advanced or metastatic disease setting and derived a clinical benefit from...
You likely can't join if
- Previous treatment with any SERDs.
- Patient any central nervous system metastasis.
- Prior antitumor therapies:
- Received chemotherapies within 3 weeks before the first dose.
- Received systemic radiotherapy within 3 weeks before the first dose, or local radiotherapy within 7 days before the first dose
- Received other anti-tumor therapy such as endocrine therapy, immunotherapy, and target therapy within 3 weeks or 5 half-lives of the drug before the...
See the full eligibility criteria
- Postmenopausal women defined as NCCN guideline at the time of informed consent.
- Histological or cytological confirmation of advanced or metastatic ER+/HER2- breast cancer women who failed standard therapy or for which no standard therapy exists.
- Prior therapy:
- No more than 1 line of chemotherapy for advanced breast cancer
- Recurrence or progression on at least one line of endocrine therapy in the advanced or metastatic disease setting and derived a clinical benefit from the endocrine therapy: Recurred or progressed while being treated...
- ECOG score 0-1.
- Minimum life expectancy of a least 3 months as determined by the Investigator.
- Evaluable disease per RECIST 1.1; for patients consent to tissue biopsy, disease suitable for tumor biopsy.
- Sufficient bone marrow reserve and organ function. Key
- Previous treatment with any SERDs.
- Patient any central nervous system metastasis.
- Prior antitumor therapies:
- Received chemotherapies within 3 weeks before the first dose.
- Received systemic radiotherapy within 3 weeks before the first dose, or local radiotherapy within 7 days before the first dose
- Received other anti-tumor therapy such as endocrine therapy, immunotherapy, and target therapy within 3 weeks or 5 half-lives of the drug before the first dose of the study drug
- For bone metastasis, bisphosphonates and local remission therapy are allowed (7 days washout for local radiation therapy).
- Patient who has participated in any other clinical trials for drugs or treatments within 5 half-lives for a prior investigational drug or 2 weeks from use of an investigational device prior to the first dose of study...
- Patient who had major surgery or significant trauma within 4 weeks prior to the first dose of study drug (excluding needle biopsy), or has scheduled surgery during the study period.
- Patient with serous unhealable wounds/ulcers/fractures within 4 weeks prior to the first dose of study drug.
- Patient with adverse reactions to previous anti-tumor treatments who have not yet recovered to grade ≤1 according to CTCAE v5.0. (except for toxicities without safety risks as judged by Investigator, such as alopecia...
- Patient who has used strong inhibitors or strong inducers of CYP3A, or grapefruit or grapefruit juice within 4 weeks prior to the first dose of study drug.
- Patient unable to be administered oral medications or any condition that seriously affect digestion in the gastrointestinal tract at the judgement of the Investigator.
- Patient with active infection within 1 week prior to the first dose of study drug, and currently need systemic anti-infective treatment.
- Patient has a known history of the following: HIV infection without effective antiretroviral therapy (ART) or acceptable immune function, or syphilis infection, or HBsAg positive HBV or needs prophylaxis therapy or...
- Patient has active cardiac disease or a history cardiac dysfunction.
- Patient with third spacing that cannot be controlled clinically and is not suitable for the study by the Investigator's judgment.
- Patient with known history of drug abuse.
- Patient with mental disorder that, in the opinion of the Investigator, could lead to poor compliance with required study procedures.
- Patient that cannot tolerate venous blood sampling.
- Known to have other malignancy within the past 5 years, and is progressing or requires active treatment (except skin basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ who have received...
The study team makes the final eligibility decision.
Where it's taking place
- Nashville, Tennessee, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nashville, Tennessee, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.